Ignite Creation Date:
2025-12-24 @ 7:09 PM
Ignite Modification Date:
2025-12-29 @ 6:29 AM
Study NCT ID:
NCT02116803
Status:
COMPLETED
Last Update Posted:
2018-03-01
First Post:
2014-04-15
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05-28
Start Date Type:
ACTUAL
Primary Completion Date:
2016-11-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-11-28
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-15
First Submit QC Date:
None
Study First Post Date:
2014-04-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-10-20
Results First Submit QC Date:
None
Results First Post Date:
2018-02-01
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2018-01-31
Last Update Post Date:
2018-03-01
Last Update Post Date Type:
ACTUAL